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Abstract
Background: TEX101 is a cell membrane protein exclusively expressed by testicular germ cells and shed into
seminal plasma. We previously verified human TEX101 as a biomarker for the differential diagnosis of azoospermia,
and developed a first-of-its-kind TEX101 ELISA. To demonstrate the clinical utility of TEX101, in this work we aimed
at evaluating ELISA performance in a large population of fertile, subfertile, and infertile men.
Methods: Mass spectrometry, size-exclusion chromatography, ultracentrifugation, and immunohistochemistry were
used to characterize TEX101 protein as an analyte in seminal plasma. Using the optimized protocol for seminal
plasma pretreatment, TEX101 was measured by ELISA in 805 seminal plasma samples.
Results: We demonstrated that TEX101 was present in seminal plasma mostly in a free soluble form and that its
small fraction was associated with seminal microvesicles. TEX101 median values were estimated in healthy, fertile
pre-vasectomy men (5436 ng/mL, N = 64) and in patients with unexplained infertility (4967 ng/mL, N = 277),
oligospermia (450 ng/mL, N = 270), and azoospermia (0.5 ng/mL, N = 137). Fertile post-vasectomy men (N = 57) and
patients with Sertoli cell-only syndrome (N = 13) and obstructive azoospermia (N = 36) had undetectable levels of
TEX101 (≤0.5 ng/mL). A cut-off value of 0.9 ng/mL provided 100% sensitivity at 100% specificity for distinguishing
pre- and post-vasectomy men. The combination of a concentration of TEX101 > 0.9 ng/mL and epididymis-specific
protein ECM1 > 2.3 μg/mL provided 81% sensitivity at 100% specificity for differentiating between non-obstructive
and obstructive azoospermia, thus eliminating the majority of diagnostic testicular biopsies. In addition, a cut-off
value of ≥0.6 ng/mL provided 73% sensitivity at 64% specificity for predicting sperm or spermatid retrieval in
patients with non-obstructive azoospermia.
Conclusions: We demonstrated the clinical utility of TEX101 ELISA as a test to evaluate vasectomy success, to
stratify azoospermia forms, and to better select patients for sperm retrieval.
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Background
Infertility is a common medical condition with an esti-
mated prevalence of nearly 15% in the general popula-
tion [1]. The disorder affects both men and women,
while the male factor, exclusively or combined with fe-
male abnormalities, contributes to approximately 50% of
all cases. The clinical categories of male infertility range
from lowered production of sperm, or oligospermia, to se-
vere cases of azoospermia with non-measurable levels of
sperm in semen [2]. Azoospermia is diagnosed in nearly
2% of the general population and has two major forms,
non-obstructive (NOA) and obstructive azoospermia
(OA). Based on histological evaluation of testicular tissue,
the NOA subtype is further classified into hypospermato-
genesis (HS), maturation arrest (MA), and Sertoli cell-only
syndrome (SCO) [3]. OA results from physical obstruction
in the male reproductive tract due to congenital or ac-
quired defects in the epididymis or vas deferens [4]. A
diagnostic testicular biopsy is used to evaluate the rate of
spermatogenesis and the presence of sperm in the testis,
and it remains the standard tool for differential diagnosis
of azoospermia [5]. However, it is an invasive surgical pro-
cedure with potential complications. Thus, there is an ur-
gent need for alternative, non-invasive approaches for
differential diagnosis of male infertility and further classifi-
cation of its subtypes.
Seminal plasma (SP) is enriched with testis-derived
proteins, mRNA, and metabolites. It has been proposed
as a suitable clinical sample for the non-invasive diagno-
sis of a wide range of male reproductive system disor-
ders [6–8]. SP contains up to 3200 proteins secreted by
testes, epididymis, prostate, seminal vesicles, and Cow-
per’s glands [9, 10]. Numerous proteins found in SP are
directly involved in the production and maturation of
sperm or in the interaction with the zona pellucida and
fusion with oocytes [11]. Because testis-specific bio-
markers are not found in blood serum due to stringent
blood–testis and blood–epididymis barriers, semen and
SP remain the only viable fluids for the non-invasive
diagnosis of male infertility [12, 13].
We previously proposed a simple two-biomarker algo-
rithm for the non-invasive differential diagnosis of azoo-
spermia [14]. Two proteins, the testis-specific protein
TEX101 and the epididymis-expressed protein ECM1
were verified and validated as biomarkers for the differen-
tial diagnosis of NOA versus OA [9, 11]. In addition,
TEX101 levels in SP facilitated further classification of
NOA subtypes into HS, MA, and SCO [14]. Mass
spectrometry-based selected reaction monitoring (SRM)
and immuno-SRM assays were initially used to measure
TEX101 in SP, but translation of those assays into routine
clinic practice required the higher throughput, better sen-
sitivity, and greater simplicity of ELISA [15]. Recently, we
generated monoclonal antibodies, developed TEX101
ELISA, and optimized SP handling and pretreatment pro-
tocols in order to increase assay sensitivity [16].
Previously, we proposed the clinical utility of TEX101
as a biomarker based on its measurements in SP by
mass spectrometry [14]. In this work, we focused on the
full characterization of TEX101 as an analyte in SP; the
preclinical evaluation of the performance of TEX101
ELISA in a large cohort of fertile, subfertile, and infertile
men; and the validation of TEX101 as a prognostic bio-
marker of male infertility and a predictive biomarker of
sperm retrieval in NOA patients. Our objective was also
to evaluate TEX101 ELISA as a test for the differential
diagnosis of the most common clinical conditions of
male infertility (unexplained infertility, oligospermia, and
azoospermia) and to propose simple decision trees for
use in the clinic. We hypothesized that TEX101 levels in
SP would vary in patients with different categories of
male infertility. We would suggest that the TEX101 test
is offered after the standard protocols for the initial
evaluation of infertility (semen analysis and measure-
ment of motility, morphology, and levels of reproductive
hormones) in patients admitted to urology clinics, but
prior to diagnostic testicular biopsies. The presented
study was based on retrospectively collected SP samples
(Fig. 1) and followed the Standards for Reporting Diag-
nostic Accuracy Studies (STARD 2015) statement [17],
to demonstrate the performance of our TEX101 ELISA,
and to propose three distinct clinical utilities of our test.
Methods
Experimental design and statistical rationale
Based on our previous measurements of TEX101 by
ELISA [16], the minimal sample size required to validate
TEX101 performance in pre- and post-vasectomy groups
was 18 samples (two-tailed Mann–Whitney U test, α =
0.05, 80% power, allocation ratio of 1). Even though the
minimal sample size was small, we decided to measure
TEX101 in all SP samples available in our biobank in
order to establish more accurate clinical cut-off values.
Patients with inclusion and exclusion criteria
Healthy, fertile men pre- and post-vasectomy, and men
referred to Mount Sinai Hospital for clinical infertility
evaluation were included in the study. Initial patient
evaluation included computer-assisted semen analysis
and measurement of reproductive hormones (testoster-
one, estradiol, follicle-stimulating hormone, luteinizing
hormone, and prolactin). Sperm concentration, ejaculate
volume, motility, and morphology were graded based on
World Health Organization 5th edition criteria [18].
Azoospermia was defined as no sperm found on the ini-
tial semen analysis, and oligospermia included men with
spermatozoa present at concentrations <15 million/mL.
Unexplained infertility was defined as the inability to
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conceive after 1 year of regular unprotected intercourse,
spermatozoa concentration >15 million/mL, and normal
hormonal parameters. Note that we did not have female
factor data for this group. There are a number of female
infertility factors, such as tubal obstruction, endometri-
osis, polycystic ovary syndrome, among many others,
that make female factor infertility a determinant or co-
determinant. Thus, some patients in this group may in
fact have been healthy, fertile men. Clinical reference
standards for vasectomy were sperm counting, while
clinical reference standards for OA, NOA and sperm re-
trieval were sperm counting, diagnostic testicular biop-
sies, and testicular sperm extraction (TESE). Clinical
cut-off values were reported based on the randomized
blind measurements of TEX101 in 805 retrospectively
collected SP samples using ELISA with the sodium
deoxycholate (DOC)-based protocol. The analysis did
not include 45 patients for whom SP samples were fully
consumed in the preliminary experiments.
Seminal plasma samples
Following collection, semen was left to liquefy at room
temperature (RT) for 1 h, then aliquoted and centrifuged
three times at 13,000 × g for 15 min. SP was separated
from cells and cellular debris and stored at −80 °C.
TEX101 ELISA measurements
The 96-well ELISA plates were coated with 500 ng/well
of mouse monoclonal anti-TEX101 antibody 23ED616.8
in 50 mM Tris-HCl buffer at pH 7.8. Plates were washed
twice with the washing buffer (0.05% Tween20 in
20 mM Tris-HCl and 150 mM NaCl at pH 7.4). Assay
calibrators were prepared as previously described [16].
Briefly, several dozen SP samples from fertile pre-
vasectomy men were pooled, and endogenous TEX101
concentration (4.7 ± 1.5 μg/mL) was measured by SRM.
Multiple 20 μL aliquots of the pool were stored at −20 °
C. For ELISA measurements, calibrators and patient
samples were thawed and mixed (1:1) with either
Reagent mixture #1 (6 M guanidinium chloride [GndCl]
at pH 12; 1 h incubation at RT) or Reagent mixture #2
(4% DOC in water; incubation for 1 h at 63 °C). Follow-
ing treatment, calibration samples were diluted 100-fold
with the assay diluent (60 g/L bovine serum albumin
[BSA], 25 mL/L normal mouse serum, 100 mL/L normal
goat serum, and 10 g/L bovine IgG in 50 mM Tris-HCl
at pH 7.8). Subsequently, serial dilutions of the treated
calibrator (0.5–50 ng/mL, 100 μL/well) were prepared
with 4-fold dilution steps. Similarly, patient SP samples
(20 μL) were treated with Reagent mixture #1 or 2 (1:1),
further diluted 10-, 100-, 1000-, and 10,000-fold with the
assay diluent, and added on ELISA plates (100 μL/well).
Following 2 h of incubation with gentle shaking, plates
were washed twice with the washing buffer. A biotinylated
mouse monoclonal anti-TEX101 antibody 23ED660.7 in
the assay diluent (250 ng in 100 μL per well) was added
and incubated for 1 h. Plates were then washed six times,
and streptavidin-conjugated alkaline phosphatase was
added for 15 min with gentle shaking. After the final wash
(six times), diflunisal phosphate solution was prepared in
Fig. 1 Flowchart of the study. SP seminal plasma
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the substrate buffer (0.1 M NaCl, 1 mM MgCl2 in 0.1 M
Tris at pH 9.1), added to the plate (100 μL per well), and
incubated for 10 min at RT with gentle shaking. Finally,
the developing solution (1 M Tris-HCl, 0.4 M NaOH,
2 mM TbCl3, and 3 mM EDTA) was added and mixed for
1 min. Time-resolved fluorescence was measured with the
Wallac EnVision 2103 Multilabel Reader (Perkin Elmer),
as previously described [19].
Measurement of TEX101 isoforms in spermatozoa and
seminal plasma by selected reaction monitoring
SP and spermatozoa of patients with a normal sperm
count (median 26 million/mL; N = 17) were prepared.
Spermatozoa were lysed by RapiGest SF Surfactant
(Waters Corp., Milford, MA, USA). The total protein
was measured by bicinchoninic acid (BCA) assay, and 5
and 10 μg of total protein of spermatozoa lysate and SP,
respectively, were mixed with 50 mM ammonium bicar-
bonate. SRM assays were developed using previously de-
scribed selectivity and reproducibility criteria [20–22].
Two hundred fmoles of the heavy isotope-labeled TEX101
peptide AGTETAILATK (present in both membrane/se-
creted isoform Q9BY14-1 and intracellular isoform
Q9BY14-2) and 500 fmoles of heavy isotope-labeled pep-
tide QIQTSSSQTSPEEAMGTPR (present exclusively in
the intracellular isoform Q9BY14-2) were spiked before
trypsin digestion. Heavy isotope-labeled peptides (SpikeTi-
desTM_TQL, JPT Peptide Technologies GmbH, Berlin,
Germany) included trypsin-cleavable quantifying JPT tags
(serine-alanine-[3-nitro]tyrosine-glycine). Five millimoles
of dithiothreitol (DTT) (Sigma-Aldrich, St. Louis, MO,
USA) and 0.05% RapiGest SF Surfactant were added, and
samples were incubated at 60 °C for 30 min. Following
that, samples were alkylated in the dark with 10 mM
iodoacetamide (Sigma-Aldrich) for 40 min and digested
overnight at 37 °C with proteomics-grade porcine trypsin
(Sigma-Aldrich, #T6567). Trypsin inactivation and cleav-
age of RapiGest SF was achieved with the addition of tri-
fluoroacetic acid (1% final). Additionally, 5 mM of L-
methionine (Sigma-Aldrich) was added to each digest, in
order to limit the oxidation of methionine residues during
sample preparation or storage. Finally, digests were loaded
on C18 OMIX tips (Varian Inc., Lake Forest, CA, USA),
and bound peptides were eluted in 3 μL of 65% aceto-
nitrile in water with 0.1% formic acid. Water with 0.1%
formic acid was added (60 μL final volume), and samples
were transferred to the 96-well microplate (Axygen, Union
City, CA, USA).
Using a 96-well microplate autosampler, 18 μL of each
sample were loaded onto a 3 cm trap column (inner diam-
eter 150 μm; New Objective, Woburn, MA, USA) packed
in-house with 5 μm Pursuit C18 (Varian). An increasing
concentration of Buffer B (0.1% formic acid in acetonitrile)
was used to elute the peptides from the trap column onto
a resolving analytical 5-cm PicoTip emitter column (inner
diameter 75 μm, 8 μm tip; New Objective) packed in-
house with 3 μm Pursuit C18 (Varian). The EASY-nLC
system (Proxeon Biosystems) was coupled online to a
TSQ QuantivaTM triple quadrupole mass spectrometer
(Thermo Scientific, San Jose, CA, USA) with a nanoelec-
trospray ionization source. The SRM parameters were as
follows: positive polarity, declustering and entrance poten-
tials of 150 and 10 V, respectively; ion transfer tube
temperature 300 °C; optimized collision energy values;
scan time 40 ms; 0.4 and 0.7 Da full width at half max-
imum resolution settings for the first and third quadru-
poles, respectively; and 1.5 mTorr argon pressure in the
second quadrupole. TEX101 peptides were monitored in a
non-scheduled SRM mode during a 30 min LC gradient
(Additional file 1: Table S1). The relative abundance of
TEX101 in each sample was estimated as a ratio of the en-
dogenous peptide to the spiked heavy isotope-labeled
standards. Raw files for each sample were recorded and
analyzed with Skyline software (v3.1.0.7382, MacCoss Lab
Software, Seattle, WA, USA).
Immunohistochemistry of TEX101 in testicular tissues
In-house-generated mouse monoclonal anti-TEX101
antibodies 23-ED-660, 23-ED-11, and 23-ED-228 were
used to stain testicular tissue samples fixed with 10%
buffered formalin. Samples were incubated with the anti-
body solutions for 1 h at RT. Multiple dilutions (400- to
5000-fold) were tested. Heat-induced epitope retrieval
was performed in citrate buffer at pH 6.0. A Vectastain
Elite ABC Kit (Vector Laboratories Inc., Burlingame,
CA, USA), 3,3'-diaminobenzidine substrate (Sigma-Al-
drich), and a LabVision 720 autostainer (Thermo Fisher
Scientific Inc.) were used for detection.
Size-exclusion chromatography
SP samples from pre-vasectomy men were centrifuged at
4000 × g for 20 min and pooled (total protein 39 mg/mL).
A vesicle-free pool (total protein 22 mg/mL) was obtained
by ultracentrifugation at 120,000 × g. Five hundred micro-
grams of total protein from both pools were diluted to
500 μl with the running buffer (0.1 M NaH2PO4-
Na2HPO4 and 0.15 M NaCl at pH 7.0) and loaded on a
TSKgel G3000SW size exclusion column (Tosoh Bio-
science LLC, King of Prussia, PA, USA). Pools were run at
1 mL/min for 35 min, and fractions were collected every
0.5 min from 8 to 27 min. The presence of TEX101 in
each fraction was measured by ELISA with DOC-based
treatment.
Isolation of seminal microvesicles from seminal plasma
samples
Pre- and post-vasectomy SP samples, as well as four sam-
ples obtained from the group of infertile individuals with
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moderate-to-high sperm count, were individually pooled.
Seminal microvesicles (SMVs) were isolated with a
method adapted from Fabiani et al. [23]. Semen samples
were centrifuged at 4000 × g for 20 min at 4 °C to remove
cells and cell debris. The remaining supernatants were di-
luted 1:2 in a solution containing 30 mM Tris and
130 mM NaCl at pH 7.5 and centrifuged one more time
at 4000 × g for 20 min at 4 °C. Following that, superna-
tants were ultracentrifuged at 120,000 × g for 2 h at 4 °C,
pellets were re-suspended in 30 mM Tris and 130 mM
NaCl at pH 7.5, and finally subjected to size-exclusion
chromatography on a Sephacryl S-500 HR (15 × 85 mm;
Pharmacia Canada Ltd, Dorval, QC, Canada) for mem-
branous vesicle purification. The eluate was collected into
18 fractions (0.5 mL). The SMV-positive fractions were
detected by elevated absorbance at 280 nm. Fractions 8–
15 were pooled (4 mL) and ultracentrifuged at 120,000 × g
for 2 h at 4 °C to pellet the SMVs. The pellets were resus-
pended in phosphate-buffered saline (PBS) at pH 7.4 and
stored with matched vesicle-free SP samples at −80 °C.
The amount of total protein was assessed by BCA assay
(Pierce Biotechnology, Rockford, IL, USA).
TEX101 measurement in pooled seminal plasma samples,
seminal microvesicles, and vesicle-free seminal plasma by
ELISA
SMVs, vesicle-free SP, and the original pooled pre- or
post-vasectomy or infertile SP samples were mixed with
corresponding reagent mixes (1:1) and incubated for 1 h
either at RT or at 63 °C. Mixtures were further diluted
with ELISA diluents before loading on the plate. Ana-
lysis was accomplished as described above.
TEX101 measurement in pooled seminal plasma samples,
seminal microvesicles, and vesicle-free seminal plasma by
selected reaction monitoring
TEX101 concentrations in the original SP pools, SMVs,
and vesicle-free fractions were calculated using the SRM
assay described above. Ten micrograms of total protein
from each sample was subjected to trypsin digestion.
Heavy isotope-labeled peptide with a trypsin-cleavable
tag AGTETAILATK*-JPTtag was used as an internal
standard for absolute quantification of TEX101 protein.
TEX101 measurement in seminal plasma by
immunocapture-selected reaction monitoring
Immunocapture-SRM assay was used to investigate the
effect of SP pretreatment on antibody–antigen interac-
tions. Initially, a pool of SP was prepared and subjected
to various types of treatment prior to analysis. Treat-
ment options included: (i) mixing (1:1) with 6 M GndCl
(pH 12) and incubation at RT for 1 h, (ii) mixing (1:1)
with 4% DOC and incubation at RT for 1 h, (iii) mixing
(1:1) with 6 M GndCl (pH 12) and incubation at 63 °C
for 1 h, (iv) mixing (1:1) with 4% DOC and incubation at
63 °C for 1 h, and (v) incubation at 63 °C for 1 h. Non-
treated SP was also included in the analysis. According
to the established protocol [16], white 96-well microtiter
plates were coated with 500 ng per well of purified
mouse immunoglobulins in 50 mM Tris-HCl at pH 7.8.
Antibodies used for coating included a commercial
mouse polyclonal anti-TEX101 antibody (ab69522;
Abcam, Cambridge, MA, USA), an in-house-generated
mouse monoclonal anti-TEX101 antibody (23ED616.8),
and a mouse IgG (Equitech-Bio, Inc., Cat. #M60) as an
isotype control. Following overnight incubation at RT,
plates were washed twice with PBS. Three dilutions
(×10, ×100, ×1000) of pretreated SP samples in 6% BSA
in PBS were loaded onto the plate (100 μL per well) and
incubated for 2 h at RT with gentle shaking. Following
that, plates were washed three times with PBS and three
times with 50 mM ammonium bicarbonate. A mix con-
taining 50 mM ammonium bicarbonate, 5 mM DTT,
and 100 fmoles of heavy isotope-labeled TEX101 peptide
AGTETAILATK*-JPTtag was added to each well and in-
cubated for 30 min at RT. Subsequently, 10 mM iodoace-
tamide was added and samples were kept for 40 min in
the dark at RT. L-methionine (5 mM final) was added to
prevent methionine oxidation in tryptic peptides. Extrac-
tion of peptides from solution and SRM quantification
were accomplished as mentioned above. Raw files for each
sample were recorded and analyzed with Skyline software,
and peptide areas were used to calculate light-to-heavy ra-
tios and TEX101 concentration in each sample.
Statistics
Power calculations were done with G*Power software
(version 3.1.7, Heinrich Heine University, Dusseldorf,
Germany). GraphPad Prism (v4.0; Graphpad Software,
San Diego, CA, USA) was used to generate scatterplots,
perform statistical analysis, and calculate the area under
the Receiver Operating Characteristic curve (ROC AUC)
and diagnostic sensitivity and specificity. Comparisons
for two groups were made using the non-parametric
Mann–Whitney U test, while multiple groups were
analyzed by Kruskal–Wallis test, followed by Dunn’s
multiple comparison test. Because only 30 of 64 pre-
vasectomy samples were matched to post-vasectomy
samples, unpaired Mann–Whitney U analysis was ap-
plied. All hypotheses testing was two-tailed, and P-values
<0.05 were considered statistically significant. The assay’s
reference interval was estimated using the pre-vasectomy
SP samples. TEX101 values were log10-transformed and
the lower and upper 95% confidence interval (CI) of the
arithmetic mean was calculated. Correlations between
TEX101 concentration and other continuous variables
were assessed by Spearman correlation coefficients (rs).
For the first and second intended uses (evaluation of
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vasectomy efficiency and differential diagnosis of azoo-
spermia forms), the cut-offs and sensitivities were deter-
mined based on 100% specificity. For the third intended
use (prediction of sperm retrieval), the cut-off, sensitivity,
and specificity were exploratory. Samples with missing
data were not used in calculations.
Study approval
Semen samples were obtained with informed consent
from patients by masturbation with 2–5 days of abstin-
ence before collection. Eight hundred and fifty (N = 850)
semen samples were obtained from healthy, fertile men
and patients diagnosed with unexplained infertility, oligo-
spermia, and azoospermia (Table 1). Sample collection
was approved by the institutional review boards of Mount
Sinai Hospital (approval #08-117-E) and University Health
Network (#09-0830-AE). Samples were collected as a con-
venience series and analyzed retrospectively. The time dif-
ference between initial sperm count measurements in
semen and TEX101 measurements in SP varied from sev-
eral months to up to 5 years.
Results
Measurement of TEX101 in 821 seminal plasma samples
using guanidine-based treatment protocol
We initially measured TEX101 in 821 SP samples ob-
tained from healthy fertile men pre- and post-vasectomy,
as well from patients with unexplained infertility, oligo-
spermia, and OA and NOA. SP samples and ELISA stan-
dards were treated with 3 M GndCl at pH 12 for 1 h at
RT, before analysis.
Results revealed high TEX101 concentrations in SP of
fertile pre-vasectomy men (median 3433 ng/mL, N = 65),
while it was undetectable in post-vasectomy men (me-
dian 0.5 ng/mL, N = 61). Similarly, TEX101 values were
high in the group of men with unexplained infertility
(median 2875 ng/mL, N = 276) and were significantly re-
duced in oligospermia (median 270.5 ng/mL, Mann–
Whitney U test P < 0.0001, N = 269) and azoospermia
(median 0.5 ng/mL, Mann–Whitney U test P < 0.0001,
N = 150) samples (Additional file 2: Table S2 and
Additional file 3: Figure S1). Because TEX101 is a germ
cell-specific protein, we expected a strong correlation
between its concentration in SP and the number of germ
cells or spermatozoa in semen. The correlation between
measured TEX101 concentration (ng/mL) and the sperm
count (million/mL), however, was of moderate strength
(rs = 0.74). In addition, we noticed that a small fraction
of patients (N = 17) with unexplained infertility (sperm
count >15 million/mL) and oligospermia (sperm count
>7 million/mL) had undetectable levels of TEX101
(<0.5 ng/mL) in SP (Additional file 4: Table S3). It
should be mentioned that previous studies of Tex101−/−
mouse knockout models revealed normal phenotypes,
normal sperm morphology, and high sperm count, but
absolute sterility of male mice [24]. Thus, we decided to
examine in detail samples from these 17 patients with al-
ternative methods, such as SRM mass spectrometry.
We thus measured TEX101 by SRM in SP and
matched spermatozoa of the 17 patients with a
high sperm count and undetectable TEX101 protein
(Additional file 4: Table S3). TEX101 protein was de-
tected in both SP and spermatozoa in all 17 patients. This
allowed us to exclude the hypothesis of TEX101 gene
knockouts in those patients. Additional examination of re-
cent genomic data for loss-of-function mutations in
TEX101 supported our conclusions. According to the
ExAC Browser (http://exac.broadinstitute.org), stop gain,
frameshift, and splice donor mutations in TEX101 were
are and detected with the allele frequency <0.004% in a
general population of 60,692 individuals.
Isoform identity of TEX101 in spermatozoa and seminal
plasma
According to UniProt (www.uniprot.org), alternative
splicing of human TEX101 results in two isoforms: an
extracellular membrane-bound isoform Q9BY14-1 (249
amino acids) and an intracellular isoform Q9BY14-2
(267 amino acids). To further investigate the identity of
TEX101 in SP, we developed an SRM assay for the pep-
tide QIQTSSSQTSPEEAMGTPR that was unique for
Table 1 Clinicopathological variables of the patient cohort
Clinical parameters Number Percentage
Number of subjects 850 100







Middle Eastern 27 3.2
Native-Canadian 11 1.3
Unspecified/unavailable 423 49.8
Diagnosis (sperm count in million/mL)
Pre-vasectomy 67 (>15) 7.9
Post-vasectomy 63 (0) 7.4
Unexplained infertility 283 (15–360) 33.3
Oligospermia 276 (0.01–15) 32.5
Azoospermia 20 (0–0.5) 2.3
Non-obstructive azoospermia 100 (0–0.24) 11.8
Obstructive azoospermia 39 (0–0.18) 4.6
Unknown diagnosis 2 0.2
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the intracellular isoform Q9BY14-2 (Additional file 5:
Figure S2). We hypothesized that the intracellular iso-
form Q9BY14-2 could be exclusively expressed in those
17 samples, but was not captured by our monoclonal
antibody (generated against the extracellular isoform
Q9BY14-1) and measured by ELISA. SRM measurements
in SP and spermatozoa in these 17 samples revealed the
absence of intracellular isoform Q9BY14-2 and the exclu-
sive presence of the extracellular membrane-bound iso-
form Q9BY14-1 (Fig. 2).
Confirmation of TEX101 germ cell-specificity and extracel-
lular membrane localization by immunohistochemistry
Previously, TEX101 protein expression in testicular tissues
was studied using rabbit polyclonal antibodies generated
against TEX101 peptide fragments (Atlas Antibodies
HPA041915 and HPA042513). Here, we stained testicular
tissues with normal spermatogenesis using our monoclo-
nal antibody 23ED228, generated against the full TEX101
protein. We observed more intense staining of germ cells
and lower background with our antibody at a final
concentration of 80 ng/mL, versus 400 ng/mL for
HPA041915 antibody. We observed no staining of Leydig,
Sertoli, or spermatogonia cells; very weak cytoplasmic and
membrane staining in primary spermatocytes; and very
intense extracellular/membrane staining in secondary
spermatocytes, spermatids, and testicular spermatozoa.
Immunohistochemistry confirmed the exclusive expres-
sion of TEX101 in germ cells and its localization to the
extracellular membrane (Fig. 3).
Fig. 2 Investigation of TEX101 isoforms in spermatozoa and seminal plasma (SP) using selected reaction monitoring (SRM). Semen samples from men
with a high sperm count (≥7 million/mL) and unexplained infertility and oligospermia (N = 17, see Additional file 4: Table S3) were centrifuged to
separate spermatozoa from SP, which were then analyzed by SRM. Peptide AGTETAILATK common for both isoforms was used to quantify total
TEX101, while unique peptide QIQTSSSQTSPEEAMGTPR was used to detect the presumed intracellular TEX101 isoform Q9BY14-2. Corresponding heavy
isotope-labeled peptides were used as internal standards. Intracellular isoform Q9BY14-2 was not detected in either spermatozoa or SP, so total TEX101
was assumed to be a 249 amino acid (aa) extracellular membrane isoform Q9BY14-1. The checkmark indicates detection and X the absence of the
peptides shown
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Search for soluble TEX101 complexes in seminal plasma
by size-exclusion chromatography
Previously, it was suggested that mouse TEX101 was in-
volved in protein–protein interactions prior to its cleav-
age from the cell surface and release into SP [24, 25].
Because potential complexes of human TEX101 might
hamper its capture or detection by antibodies with
ELISA test, we used size-exclusion chromatography to
investigate the presence of soluble TEX101 complexes in
the pool of pre-vasectomy SP. Following DOC pretreat-
ment at 63 °C of SP, ELISA was used to measure the
level of TEX101 in each fraction. Results revealed that
TEX101 was eluted as a single peak with 28 kDa size, as
estimated by size-exclusion chromatography standards
(Fig. 4a). This molecular weight was in good agreement
with our previous estimates by western blot (~30 kDa
for the glycosylated form and ~20 kDa for a deglycosyl-
ated form after PNGaseF treatment) [16].
We assumed that putative TEX101 complexes with
other proteins would elute within fractions correspond-
ing to higher molecular weights (i.e., >30 kDa). However,
we detected negligible amounts of TEX101 (<8%) in
those fractions (Fig. 4a, before ultracentrifugation) and
concluded that the majority of TEX101 was present as an
unbound free soluble form. We also noted that some
TEX101 (~14% of total) was found in fractions correspond-
ing to high-molecular weight molecules (>500 kDa) and the
void volume. Ultracentifugation at 120,000 × g of the same
pre-vasectomy SP pool followed by size-exclusion chr-
omatography (Fig. 4a, after ultracentrifugation) resulted in
non-detectable TEX101 in those high-molecular weight
fractions. We thus hypothesized that a fraction of TEX101
might be associated with the debris of spermatozoa cellular
membranes, exosomes, or SMVs.
TEX101 association with seminal microvesicles in seminal
plasma
All the above-mentioned experiments suggest that the
failure of ELISA to measure low amounts of TEX101 in
some SP samples (17 samples from unexplained infertil-
ity and oligospermia groups) was not related to TEX101
mutant forms, intracellular isoforms, or soluble com-
plexes. To investigate if TEX101 was associated with
SMVs, we pooled four of these 17 SP samples (two from
each group) and isolated SMVs by centrifugation at
120,000 × g. As a control, we also isolated SMVs from
pools of pre- or post-vasectomy SP samples. SMVs were
denaturated with RapiGest SF at 65 °C, proteins were
digested by trypsin, and TEX101 was quantified by the
antibody-independent SRM assay in SMVs, matched
vesicle-free supernatants, and original SP pools. Results
confirmed the presence of TEX101 in SMVs and vesicle-
free fractions of the four-sample infertility pool, as well as
of the pre-vasectomy pool (Additional file 6: Figure S3).
TEX101 levels in SMVs, matched vesicle-free supernatants,
and initial SP of the post-vasectomy pool were below the
limit of detection (LOD; 27 pg/μg of total protein).
We also measured by SRM in the pre-vasectomy SP
and corresponding SMVs three highly tissue-specific se-
creted proteins that represent major glands in the male
urogenital system. We detected high amounts of KLK3
(prostate-specific protein; 4.14 ng/μg of total protein),
SEMG1 (seminal vesicle-specific protein; 37.3 ng/μg),
Fig. 3 Immunohistochemical staining of TEX101 protein in testicular tissue with active spermatogenesis. a Testicular tissue stained with our
monoclonal antibody 23ED228 (final concentration 80 ng/mL). Cell types presented include Sertoli cells (negative staining), Leydig cells (negative
staining), and germ cells at different stages of spermatogenesis, such as spermatogonia (negative), primary spermatocytes (positive cytoplasm),
secondary spermatocytes (positive membrane), spermatids (positive), and spermatozoa. b Negative control (no primary antibody added). c
Hematoxylin and eosin staining of testicular tissue showing nucleus (purple) and cytoplasm (pink)
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ADAM7 (epididymis-specific protein; 0.45 ng/μg), and
TEX101 (0.14 ng/μg) in the digest of SMVs. Interest-
ingly, relative ratios of SEMG1, ADAM7, and TEX101
versus KLK3 were enriched 3.3-, 40-, and 12-fold in
SMVs relative to the initial SP. No enrichment of these
proteins (i.e., same ratios versus KLK3 in SMVs and SP)
would indicate that SMVs non-specifically absorb KLK3,
SEMG1, ADAM7, and TEX101. Substantial enrichment
of ADAM7 and TEX101 in SMVs thus suggested the spe-
cific mechanism of their association with SMVs. Such a
mechanism was previously demonstrated for ADAM7
protein [26]. Overall, the presence of prostate-, seminal
vesicle-, testis-, and epididymis-specific proteins indicates
that SMVs are produced by multiple glands in the male
urogenital system, as previously discussed [27].
We then investigated which of two SP pretreatment proto-
cols (GndCl- or DOC-based) would result in more complete
SMV lysis and release of TEX101 and thus facilitate accurate
measurement by ELISA. As a result, the same levels of
TEX101 in the pre-vasectomy SP pool were measured with
both treatment protocols in SMVs and vesicle-free SP
(Fig. 4b). Substantial amounts of TEX101 were associated
with vesicles, as previously shown by SRM. The level of
TEX101 in the post-vasectomy SMVs and vesicle-free SP pool
was below detection (<0.5 ng/mL) in all fractions (Fig. 4b).
Surprisingly, the pool of four infertility samples re-
vealed the discrepancy between two pretreatment proto-
cols. In infertile men, incubation of the original pool and
the vesicle-free fraction with DOC at 63 °C identified a
significantly higher level of TEX101 than pretreatment
with GndCl at RT. GndCl treatment was thus less effect-
ive in the initial SP compared to the SMV fraction, sug-
gesting some interaction between the SP matrix and
SMVs (Fig. 4b). Based on these findings, we decided to
re-examine the efficiency of treatments with GndCl at
RT or DOC at 63 C and investigate any parameters that
could affect the ELISA performance.
Effect of seminal plasma pretreatment on TEX101
measurements by ELISA
Immunocapture-SRM was used to investigate the impact
of SP pretreatment on the efficiency of TEX101 capture
Fig. 4 Investigation of TEX101 analyte identity in seminal plasma (SP) and the impact of SP pretreatment. a Size-exclusion chromatography was
used to investigate TEX101 association with protein complexes and seminal microvesicles (SMVs) in the pre-vasectomy SP. Using molecular
weight standards, we estimated the molecular weight of free soluble TEX101 as 28 kDa. No major complexes with other proteins were detected
in the range 70–210 kDa. Some TEX101 (~14%), however, was associated with the high-molecular weight structures (>500 kDa) and found in the
void volume. Ultracentifugation at 120,000 × g of the same pre-vasectomy SP pool followed by size-exclusion chromatography resulted in the
non-detectable TEX101 in the high-molecular weight fractions. b The effect of guanidinium chloride (GndCl)- and sodium deoxycholate (DOC)-
based treatments on TEX101 measurements by ELISA was estimated for SP pools of pre-vasectomy, post-vasectomy, or infertile men, as well as for their
corresponding vesicle-free fractions and SMVs. Dotted lines represent the ELISA limit of detection. Both GndCl- and DOC-based treatments were efficient in
the pre-vasectomy pools with high TEX101, with substantial amounts of TEX101 found associated with SMVs. GndCl-based treatment, however, was not
efficient in the pool of infertility samples with low TEX101 (~100-fold lower than amounts in the pre-vasectomy pools
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by the in-house-generated monoclonal 23ED616.8 and the
commercial polyclonal ab69522 antibodies. Aliquots of
pooled SP samples were mixed (1:1) with 6 M GndCl
(pH 12) or 4% DOC and incubated at RT or 63 °C, re-
spectively. Samples were analyzed in triplicate at 10-, 100-,
and 1000-fold dilutions (Additional file 7: Figure S4).
Results confirmed our earlier observations that
ab69522 captured the native form of TEX101 in SP. In-
cubation of SP with GndCl or DOC disrupted the cap-
ture of TEX101 by ab69522. As we showed previously
[16], 23ED616.8 had a lower affinity for native TEX101
than ab69522. Sample pretreatment with detergents at
63 °C, however, resulted in more efficient capture, at
least 10-fold higher than TEX101 capture after denatur-
ation at 63 °C without detergents. We also noted that
GndCl at 63 °C resulted in a slightly lower signal, pos-
sibly due to a higher impact on disruption of TEX101-
antibody complexes.
Both GndCl- and DOC-based protocols worked
equally well in SP with high amounts of TEX101
(~5000 ng/mL, pre-vasectomy samples). The GndCl-
based protocol was compromised only in some infertility
samples with low TEX101 levels (<300 ng/mL). Because
detection of even very low TEX101 levels would indicate
some residual spermatogenesis in testis and increased
chances for sperm retrieval, it was critical to demon-
strate the robust performance of the DOC-based proto-
col in all samples, including samples with very low
amounts of TEX101 (~0.5 ng/mL). Considering all of
the above, we re-measured our entire clinical cohort of
SP samples by ELISA using the DOC-based protocol.
Stability of TEX101 protein in semen
We previously demonstrated high stability of TEX101
protein in SP [16]. Because the use of our test may in-
volve SP collection and storage at home, and then
transportation of the whole semen prior to measure-
ments in the clinical laboratory, we assessed TEX101
stability in whole semen stored at +4 °C for up to
14 days. A semen sample from a patient with unex-
plained infertility was obtained at the infertility clinic,
allowed to liquefy at RT, and aliquoted. One aliquot
was centrifuged immediately, and TEX101 was mea-
sured in the SP by ELISA using the DOC-based proto-
col. Four other aliquots of whole semen were stored at
+4 °C for 5, 6, 9, and 14 days, centrifuged, and mea-
sured by TEX101 ELISA. As a result, TEX101 concen-
trations in SP slightly varied from day to day (2.4 ±
0.4 μg/mL, coefficient of variation = 16%), but no par-
ticular trends indicating TEX101 degradation were ob-
served (Additional file 8: Figure S5). We thus
concluded that TEX101 protein was stable in both SP
and whole semen.
Evaluation of TEX101 as a male infertility biomarker in a
population of 805 men
TEX101 levels were measured in 805 SP samples using the
DOC-based pretreatment protocol (Fig. 5a and Additional
file 9: Table S4). The assay’s LOD was calculated as 0.5 ng/
mL. TEX101 was detected in high amounts in all pre-
vasectomy samples (median 5436 ng/mL, N = 64), but was
undetectable in the post-vasectomy SP (N = 57). It should
be noted that a fraction of post-vasectomy samples
showed higher than usual background fluorescence
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(resulting in TEX101 levels between 0.5 and 0.9 ng/mL).
Such elevated background, however, did not affect the
proposed clinical cut-offs. TEX101 levels were high in the
unexplained infertility group (median 4967 ng/mL, N =
277), and significantly lower in the oligospermic (median
450 ng/mL, N = 270) and azoospermic (median 0.54 ng/
mL, N = 137) groups (Kruskal–Wallis test P < 0.0001). Like-
wise, differences between paired groups were also signifi-
cant (Dunn’s multiple comparison test P-values <0.001),
apart from the pre-vasectomy versus unexplained infertility
group (P > 0.05) and post-vasectomy versus azoospermia
(P > 0.05). Interestingly, comparison of 30 matched pre-
vasectomy (median 7014 ng/mL) and post-vasectomy men
(median 0.5 ng/mL) revealed that median TEX101 concen-
tration decreased at least 13,500-fold after vasectomy, with
the maximum decrease of 113,000 fold.
Based on 64 pre-vasectomy samples, the normal range
of TEX101 in the healthy, fertile men was estimated be-
tween 515.1 ng/mL (95% CI 386.8–686.0) and 50,360 ng/
mL (95% CI 37,817–67,065). Our data confirmed that
TEX101 was a highly informative biomarker to predict the
success of vasectomy or vasectomy reversal [11]. TEX101
at >0.9 ng/mL differentiated between pre- and post-
vasectomy samples with 100% sensitivity at 100% specifi-
city and ROC AUC 1.00 (95% CI 1.00–1.00). We thus
suggest that TEX101 has a clinical utility to non-invasively
evaluate the success of vasectomy or vasectomy reversal
(Fig. 6).
TEX101 was not a useful marker of unexplained infertil-
ity (AUC= 0.56, 95% CI 0.48–0.63, P > 0.05), but performed
well in oligospermia (AUC= 0.88, 95% CI 0.84–0.92, P <
0.001) and azoospermia (AUC= 0.99, 95% CI 0.98–1.00, P
< 0.001). A cut-off value of 496 ng/mL provided 96% sensi-
tivity at 98% specificity for distinguishing fertile pre-
vasectomy men from patients with azoospermia.
TEX101 levels were broadly distributed in the azoo-
spermia group with the unknown form (median 0.6 ng/
mL), NOA with the unknown histological subtype
(0.6 ng/mL), and in NOA-HS (70.4 ng/mL) and NOA-
MA (1.9 ng/mL). Levels in the NOA-SCO subtype and
OA were mainly below the LOD of 0.5 ng/mL (Fig. 5b).
Based on our small set of NOA samples with the biopsy-
confirmed histological subtypes, TEX101 could dif-
ferentiate between HS and SCO (Mann–Whitney U test
P = 0.0336), but not between MA and SCO (P = 0.10).
Additional studies with a larger sample size are required
to investigate if TEX101 can differentiate between histo-
logical subtypes of NOA.
Finally, the correlation between TEX101 levels and
sperm count improved (rs = 0.83, P < 0.001 with DOC-
based protocol versus rs = 0.74 with GndCl-based proto-
col), but was still not very strong (Additional file 10: Fig-
ure S6). This fact suggested that (i) TEX101 expression
per germ cell may vary in different individuals; (ii) the
fraction of TEX101 cleaved from the surface may vary;
or (iii) TEX101 was released into SP not only by epididy-
mal spermatozoa, but also by testicular germ cells.
Evaluation of TEX101 as a biomarker to differentiate
between non-obstructive azoospermia and obstructive
azoospermia
TEX101 ≥ 0.9 ng/mL differentiated between NOA
(N = 81) and OA/post-vasectomy (N= 93) with an AUC
of 0.67 (95% CI 0.59–0.75, P = 0.00012) and 32% sensitiv-
ity at 99% specificity. Thus, TEX101 alone was not a
strong marker for the non-invasive differentiation between
NOA and OA. Previously, we proposed that a combin-
ation of epididymis-specific protein ECM1 (measured by
ELISA) and TEX101 (measured by mass spectrometry)
could differentiate between NOA and OA and thus elim-
inate the majority of diagnostic testicular biopsies [14].
Here, we tested the combination of ECM1 and
TEX101, both measured by ELISA, in NOA (N = 42)
and OA/post-vasectomy (N= 70) samples. TEX101 ≥
0.9 ng/mL detected five additional NOA cases missed by
ECM1 ≥ 2.3 μg/mL and thus increased sensitivity to de-
tect NOA from 69% (ECM1 alone) to 81%, at 100% spe-
cificity. We have chosen such cut-offs to provide 100%
specificity, at the expense of lower sensitivity. Assuming
a 20% prevalence of OA in the azoospermic population,
the combination of ECM1 and TEX101 provided 100%
positive and 57% negative predictive values. All azoo-
spermia cases diagnosed as NOA by ECM1 ≥ 2.3 μg/mL
and TEX101 ≥ 0.9 ng/mL will thus be correct (32 pa-
tients), while 19% of patients diagnosed as OA based on
ECM1 < 2.3 μg/mL and TEX101 < 0.9 ng/mL (eight pa-
tients in the current set) will be actually NOA (false neg-
atives). We believe that false negatives are acceptable
because presumed OA patients would be followed up
with sperm retrieval, which would re-classify false OA as
NOA. In combination with ECM1, non-invasive differenti-
ation between NOA and OA is another clinical utility of
Fig. 5 a TEX101 levels in seminal plasma (SP) of healthy, fertile pre-
and post-vasectomy men and patients with unexplained infertility,
oligospermia, and azoospermia, as measured by ELISA, using sodium
deoxycholate (DOC)-based treatment. Median values for each group
are presented as horizontal lines. TEX101 differentiated pre-
vasectomy samples from post-vasectomy samples (Kruskal–Wallis
test with the Dunn’s multiple comparison test P-value < 0.0001),
oligospermia (P < 0.001), and azoospermia (P < 0.001), but not unex-
plained infertility (P > 0.05). b In the azoospermia group, TEX101 could
differentiate between hypospermatogenesis (HS) and Sertoli cell-only
syndrome (SCO) (Mann–Whitney U test P = 0.0336), but not between
maturation arrest (MA) and SCO (P = 0.10). c Prediction of spermatozoa
or spermatids retrieval in non-obstructive azoospermia (NOA) patients
using TEX101 ELISA and DOC-based treatment of SP. OA obstructive
azoospermia, SC sperm count, TESE testicular sperm extraction. *Female
factor is not known for this group
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TEX101 (Fig. 6). A combined ECM1 and TEX101 test may
eliminate the majority of diagnostic testicular biopsies.
Evaluation of TEX101 as a biomarker to predict sperm
retrieval in non-obstructive azoospermia patients
Twenty-six NOA patients in our cohort underwent
TESE, a surgical procedure to retrieve spermatozoa or
spermatids from the testis for use in in vitro fertilization.
Here, we evaluated the clinical utility of TEX101 to pre-
dict spermatozoa or spermatids retrieval by TESE in
NOA patients. Note that useful biomarkers to predict
sperm retrieval are currently not available. Testicular bi-
opsy followed by histological subtyping thus remains the
only practical diagnostic procedure.
Overall, the rate of successful sperm retrieval in NOA
patients was previously estimated as 53% [28]. Rates var-
ied for different histological subtypes of NOA: 81% for
HS, 21% for MA, and 31% for SCO subtypes [28]. In our
cohort of NOA samples with known histological subtypes
and measured TEX101 (20 out of 26 samples in Fig. 5c),
success rates for the corresponding subtypes were 100%,
55%, and 0%, respectively. Previously proposed bio-
markers, such as follicle-stimulating hormone in blood,
had moderate predictive efficiency (AUC= 0.72) with 70%
sensitivity at 62% specificity [29].
Analysis of our clinical cohort (Fig. 5c) revealed
TEX101 AUC = 0.69 (95% CI 0.48–0.89). With the cut-
off of ≥0.6 ng/mL, TEX101 had 73% sensitivity, 64% speci-
ficity, 70% positive, and 68% negative predictive values
(Fig. 6). Based on our small study with 26 patients,
TEX101 alone had moderate diagnostic value as a
predictor for spermatozoa or spermatid retrieval rate in
patients with NOA. Owing to its germ cell-specificity,
however, we suggest that TEX101 should be thoroughly
evaluated in a larger cohort of NOA patients.
Discussion
Immunoassays, such as sandwich ELISA, are indispens-
able tools for quantification of proteins in biological and
clinical samples. The availability of ELISAs facilitates the
clinical validation of putative protein biomarkers and en-
ables their translation into diagnostic laboratory tests. The
clear advantages of ELISAs over other methods for protein
quantification include high analytical sensitivity, selectivity
in complex biological matrices, high-throughput analysis,
low reagent costs, simple execution, and straightforward
interpretation of results [30].
Novel protein assays should be thoroughly evaluated
prior to their use in the clinic. Clinical evidence of a
novel diagnostic test includes scientific evidence (associ-
ation of an analyte with the clinical condition), analytical
performance (analytical sensitivity, selectivity, LOD, lin-
earity, and reproducibility), and clinical performance
(data to support reference ranges). It should be empha-
sized that different protein assay platforms, such as
ELISA or mass spectrometry, may result in different ref-
erence values and different diagnostic performance for
the same protein biomarker owing to different analyte
identities (peptide or protein, free or bound form, linear
or conformational epitope) and the use of different cali-
bration standards [31].
Fig. 6 Clinical utility of TEX101 ELISA as a test to evaluate vasectomy success, differentiate between non-obstructive azoospermia (NOA) and ob-
structive azoospermia (OA), and predict the success of sperm retrieval in patients with NOA. A cut-off value of 0.9 ng/mL provided 100% sensitivity
at 100% specificity, with an area under the Receiver Operating Characteristic curve (ROC AUC) of 1.00 (95% CI 1.00–1.00), for distinguishing pre-
and post-vasectomy men. A combination of TEX101≥ 0.9 ng/mL with epididymis-specific protein ECM1≥ 2.3 μg/mL provided 81% sensitivity at
100% specificity to differentiate between NOA and OA. A TEX101 cut-off value of ≥0.6 ng/mL provided 73% sensitivity at 64% specificity and ROC
AUC of 0.69 (95% CI 0.48–0.89) to predict sperm retrieval in patients with NOA. NPV negative predictive value, PPV positive predictive value
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Many novel diagnostic tests never make it to the clinic
or even clinical trials. For instance, only 22 novel
protein-based tests were approved by the Food and Drug
Administration between 1993 and 2008 [32]. To improve
the quality of diagnostic accuracy studies and facilitate
clinical trials of only true biomarkers, the Standards for
Reporting of Diagnostic Accuracy Studies (STARD)
statement was proposed [17]. A recent update of STARD
2015 suggested reporting 30 essential items for the novel
diagnostic assays. In this work, we followed STARD
2015 recommendations to present out novel TEX101
ELISA (Additional file 11: Table S5).
Our previous work on TEX101 as a biomarker of
azoospermia [14] motivated us to generate monoclonal
antibodies and develop a first-of-a-kind TEX101 ELISA
[16]. It should be noted that SP is not a conventional
fluid for clinical diagnostics and has some distinct differ-
ences, such as fast protease-mediated liquefaction, high
viscosity, and an abundance of SMVs, which can hamper
the performance of immunoassays. We realized that SP
might need additional treatment procedures to facilitate
protein quantification with high sensitivity. To improve
ELISA sensitivity, we tested multiple combinations of
detergents, temperatures, and pH values to select two
SP pretreatment protocols: GndCl (pH 12) at RT and
DOC at 63 °C [16]. Successful analysis of 10 pre- and 10
post-vasectomy samples and the scaled-up production of
monoclonal antibodies encouraged us to design the large
preclinical validation of TEX101 ELISA in a cohort of
more than 800 SP samples available in our biobank.
We first implemented our assay with a GndCl-
based protocol due to its simplicity and pretreatment
at RT. Overall, the performance of the test was im-
pressive, with absolute discrimination between healthy
pre-vasectomy men and patients with OA or post-
vasectomy. While reviewing the results, however, we no-
ticed that 17 samples from the unexplained infertility and
oligospermia groups with a substantial sperm count
(≥7 million/mL) exhibited undetectable levels of TEX101
in SP (Additional file 3: Figure S1).
Comprehensive characterization of the analyte identity
of our TEX101 ELISA was thus required. Mass spec-
trometry analysis of TEX101 in SP and spermatozoa
suggested the exclusive presence of the extracellular
membrane isoform Q9BY14-1 and the absence of intra-
cellular isoform Q9BY14-2, which could potentially be
undetectable by ELISA. Immunohistochemistry staining
of testicular tissues confirmed the exclusive expression
of TEX101 in germ cells and its extracellular membrane
localization. Our initial hypothesis for mutant TEX101
protein in the infertile men was rejected by detection of
TEX101 in both SP and corresponding spermatozoa by
mass spectrometry. Size-exclusion chromatography con-
firmed the molecular weight of TEX101 (28 kDa) and
did not reveal any additional TEX101-protein complexes
in SP, but suggested an association of a small fraction of
TEX101 with high-molecular weight structures.
Numerous studies previously suggested the presence
of SMVs, such as prostasomes and epididymosomes, in
semen [27, 33–35]. SMVs are produced by glands of the
male urogenital tract and modulate spermatozoa matur-
ation, transport, and capacitation. Even though TEX101
protein is not expressed in epididymis, it was previously
identified in the epididymosome fractions [36]. However,
it is still not clear if soluble TEX101 is simply absorbed by
epididymis-secreted vesicles or is present in the vesicles
produced in the lumen of seminiferous tubules (such as
residual cytoplasm of spermatids) and co-purified with
epididymosomes.
ELISA results revealed that both GndCl- and DOC-
based protocols performed equally well in the pre-
vasectomy pools including initial SP, vesicle-free SP, and
the SMVs fraction. However, DOC-based treatment dem-
onstrated superior efficiency in the infertility pool than
GndCl-based treatment or denaturation by heat only. We
thus believe that when TEX101 levels are very high
(~5000 ng/mL in the pre-vasectomy pool), the impact of
vesicles is negligible. However, when TEX101 levels are
very low (<300 ng/mL in the infertility pool), the impact
of SMVs becomes significant. Our results suggest that, un-
like the DOC-based protocol, the GndCl-based protocol
might not fully release TEX101 associated with SMVs in
the matrix of SP. We would like to emphasize that these
effects were noticeable only when TEX101 levels in SP
were very low.
Finally, we re-measured our SP samples using the DOC-
based pretreatment protocol. Note that the range of mea-
sured TEX101 concentrations in SP exceeded 127,000-
fold (0.5–63,825 ng/mL). This is an unprecedented range
of protein concentration in biological fluids, exceeding the
50,000-fold range for C-reactive protein [37] and 70,000-
fold range for human chorionic gonadotropin in blood
serum [38]. We defined the reference intervals of TEX101
in the healthy pre-vasectomy population and demon-
strated clinical utility of TEX101 as a biomarker to predict
the success of vasectomy or vasectomy reversal (Fig. 6).
TEX101 differentiated between pre- and post-vasectomy
samples with 100% sensitivity and 100% specificity, which
is an extraordinary performance for a protein biomarker
in biological fluids. In future, the TEX101 assay may be
implemented as a home-based test and replace hospital-
based sperm counting for patients after vasectomy or vas-
ectomy reversal.
TEX101 alone was not a highly informative marker for
non-invasive differentiation between NOA and OA (32%
sensitivity at 99% specificity). However, the combination
of TEX101 with ECM1 increased sensitivity to detect
NOA from 69% (ECM1 alone) to 81%, both at 100%
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specificity. With our two-marker test, a fraction of NOA
patients could be misdiagnosed as OA. Because TESE is
recommended for all OA patients owing to the very high
chances of sperm retrieval, all misdiagnosed patients will
undergo TESE and therefore be re-classified. The deci-
sion to proceed with TESE is critical for NOA patients,
for whom the chances of successful TESE are not known
and may be quite low. Some OA patients misdiagnosed
as NOA may choose to avoid TESE, despite being fertile
through TESE and assisted reproduction techniques.
Thus, it is acceptable to misdiagnose some NOA pa-
tients as OA, but not vice versa. We thus suggest that
differentiation between NOA and OA with ECM1 and
TEX101 is another clinical utility of TEX101. Such a test
is non-invasive and will eliminate the majority of diag-
nostic testicular biopsies.
Our test also revealed that TEX101 could be an inform-
ative biomarker to predict sperm or spermatid retrieval
(AUC= 0.69; 73% sensitivity at 64% specificity). It should
be noted that the outcome of sperm retrieval by TESE,
which is the clinical reference standard in this case, may
depend on the length of surgery and be different in differ-
ent clinics. It is still possible that some rare focal sperm-
atogenesis could be present in some seminiferous tubules,
but missed during surgery. TEX101 levels in SP may re-
flect the cumulative yield of spermatogenesis and thus be
useful to detect rare focal spermatogenesis.
The prediction of sperm retrieval by TEX101 was
comparable to other biomarkers that predict sperm re-
trieval, including seminal protein LGALS3BP (AUC =
0.76; 100% sensitivity at 45% specificity) [39], seminal
leptin (AUC = 0.59; 43% sensitivity at 75% specificity)
[40], seminal ESX1 mRNA (84% sensitivity at 28% speci-
ficity) [41], and blood serum FSH protein (AUC = 0.62;
71% sensitivity at 68% specificity) [40]. Better biomarkers
to predict sperm retrieval in NOA patients are still re-
quired. Ultimately, the germ cell-specificity of TEX101
protein warrants its thorough validation in a large co-
hort of NOA patients.
Conclusions
In this study we presented an optimized TEX101 im-
munoassay and its preclinical evaluation in a large set of
SP samples. We propose to implement our TEX101
ELISA as a clinical test to evaluate vasectomy success,
stratify azoospermia forms and subtypes, and predict the
success of sperm retrieval in NOA patients. It should be
noted that SP is a promising but unconventional fluid
for clinical diagnostics. Our work revealed potential is-
sues with SP as a fluid for clinical analyses, demon-
strated solutions for the measurement of protein
analytes in SP, and paved the road to translation of SP-
based diagnostic tests into clinical practice.
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